MMI SpA Launches Breakthrough Technology, Advancing Robotic Microsurgery with the World's Smallest Wristed Surgical Instruments

Food and Healthcare Press Releases Thursday October 29, 2020 09:50
CALCI Italy--29 Oct--PRNewswire/InfoQuest
  • First Procedures Performed with the Symani Surgical System

MMI SpA, an Italian company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the CE Mark, launch and first human use of its Symani(R) Surgical System in Europe for open microsurgical procedures. The first four robotic surgeries were successfully performed in Florence, Italy, including three complex, post-traumatic lower limb reconstructions as well as a post-oncological reconstruction of the pharynx.

"There is a clear demand for robotics in microsurgery as the limits of the human hand have already been reached. We founded MMI to develop a robotic system designed for and with microsurgeons that will improve outcomes and address unmet patient needs, particularly through supermicrosurgery techniques which are required for lymphatic and other extremely delicate procedures. We are pleased to be at the forefront of a new era in robotic surgery as we launch our Symani System in Europe," said Giuseppe Maria Prisco, co-founder and CEO of MMI.

The Symani Surgical System combines the benefits of tremor reduction and motion scaling (7-20x) with the world's smallest wristed instrumentation, offering seven degrees of freedom and dexterity beyond the reach of human hands. The system's NanoWrist(R) instruments are designed to overcome the challenges of free-flap reconstructions, replantations, congenital malformations, peripheral nerve repairs and lymphatic surgery, which together represent over one million procedures annually in the U.S. and Europe alone.

"Microsurgery and supermicrosurgery – as a tool, technique and discipline – continue to evolve. The use of robotics holds great promise to advance the specialty of microsurgery and improve care for patients affected by trauma, cancer, congenital malformations and even chronic conditions such as lymphedema," commented L. Scott Levin, MD, FACS, FAOA, Chair of the Department of Orthopaedic Surgery, Professor of the Plastic Surgery Division at the University of Pennsylvania School of Medicine, in response to the news of the first clinical cases.

"We are proud to bring this innovation to European patients and look forward to enabling surgeons worldwide to address challenging procedures on extremely small anatomy with increased precision, reproducibility and efficiency," said Hannah Teichmann, co-founder and Vice President of Clinical Development of MMI.

About MMI

Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The Symani Surgical System combines proprietary innovations including the world's smallest wristed microinstruments as well as tremor-reducing and motion scaling technologies. Together, these powerful capabilities allow more surgeons to perform microsurgery while expanding the field of supermicrosurgery. MMI is backed by international medtech investors including Andera Partners, Panakes Partners, Fountain Healthcare Partners and Sambatech.

Dr. Levin serves as a medical advisor to the company and has received financial compensation from Medical Microinstruments S.p.A.
The MMI system for robotic microsurgery is currently only commercially available in the European Economic Area. www.mmimicro.com
Photo - https://mma.prnewswire.com/media/1320169/Symani_MMI.jpg
Logo - https://mma.prnewswire.com/media/1320170/MMI_Logo.jpg

Latest Press Release

Official Best of SABCS(R) News - 2020 SABCS(R) Highlights Coverage

Register now to the Official Best of SABCS(R) News 2020 program to get a daily update on the most relevant advances in breast cancer. Encore Medical Education (www.encoremeded.com) will publish a new edition of the Official Best of SABCS(R) News from...

Population Council และ Duchesnay บรรลุข้อตกลงอนุญาตให้ใช้สิทธิในผลิตภัณฑ์คุมกำเนิด ANNOVERA(R)

องค์กรไม่แสวงหาผลกำไร Population Council และบริษัท Duchesnay บรรลุข้อตกลงอนุญาตให้ใช้สิทธิในผลิตภัณฑ์คุมกำเนิด ANNOVERA(R) (segesterone acetate and ethinyl estradiol vaginal system)...

Population Council and Duchesnay Announce New International License Agreement for ANNOVERA(R)

Today the Population Council and Duchesnay announce an exclusive license agreement to make ANNOVERA(R) (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive fully under a woman's control to protect against...

PEOPLE LIVING WITH HIV AND INDIVIDUALS AT-RISK EXPERIENCED DISRUPTION TO HIV CARE IN THAILAND: SURVEY

Results are part of the first Asia Pacific-wide survey that assesses the impact of COVID-19 pandemic on access and delivery of HIV care in the region The survey provides insights on the adoption of telemedicine as the future of HIV care The COVID-19...

Ministry of Public Health and Department of Health Service Support leverage leading technologies to expand Alternative State Quarantine (ASQ)

Ministry of Public Health (MOPH) and Department of Health Service Support (HSS) today announced they will leverage Agoda's cutting edge digital technologies to further improve accessibility and efficiency for the booking processes of Alternative States...

Related Topics